Anti-ATLA antibody binding peptides

• US 5,194,586 A
• Filed: 10/11/1990
• Issued: 03/16/1993
• Est. Priority Date: 10/13/1989
• Status: Expired due to Fees

• Current Assignee: Kuraray Company Limited
• Original Assignee: Kuraray Company Limited
• Inventors: Maeda, Yoshiaki, Kuroda, Naotaka, Yamada, Kyoko, Oka, Kiichiro, Washitani, Yukiko, Namba, Toshihiko, Shiraki, Hiroshi
• Primary Examiner(s): Cashion, Jr., Merrell C.
• Assistant Examiner(s): WALSH, STEPHEN G
• Application Number:
  US07/596,081
• Time in Patent Office: 887 Days
• Field of Search: 530/324, 530/325, 530/326, 435/7, 514/12
• US Class Current: 530/324
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2740/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: G01N 33/57426 leukemia
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids

Abstract

A peptide of the general formula:

H-X-A-Y

wherein A is a peptide fragment comprising 6 to 50 amino acids, X is a peptide fragment comprising 1 to 10 Lys, and Y is hydroxy or amino group, said peptide being capable of specifically binding to an antibody having a specificity against an adult T cell leukemia associated antigen, a reagent for measuring an antibody having a specificity against an adult T cell leukemia associated antigen which comprises the peptide, and an adsorbent for an antibody having a specificity against an adult T cell leukemia associated antigen which comprises the peptide immobilized on a carrier.

Claims

1. A peptide of the general formula:

space="preserve" listing-type="equation">H-X-A-Y

wherein A is a peptide fragment comprising 6 to 50 amino acids, X is a peptide fragment comprising 1 to 10 Lys, and Y is hydroxy or amino group, said peptide being capable of specifically binding to an antibody having a specificity against an adult T cell leukemia associated antigen, A being selected from the group consisting of;

(a) -Pro-Pro-Pro-Pro-Ser-Ser-Pro-Thr-His-Asp-Pro-Pro-Asp-Ser-Asp-Pro-Gln-Ile-Pro-Pro-Pro-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu- (SEQ ID NO;

     1),

(b) -Pro-Pro-Pro-Pro-Ser-Ser-Pro-Thr-His-Asp-Pro-Pro-Asp-Ser-Asp-Pro-Gln-Ile-Pro- (SEQ ID NO;

     28),

(c) -Pro-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu- (SEQ ID NO;

     29),

(d) -Pro-Val-Met-His-Pro-His-Gly-Ala-Pro-Pro-Asn-His-Arg-Pro-Trp-Gln-Met-Lys-Asp-Leu-Gln-Ala-Ile-Lys-Gln-Glu-Val-Ser-Gln-Ala-(SEQ ID NO;

     30),

(e) -Gly-Leu-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-Ala-Tyr-Ser-Asn-Ala-Asn-Lys-Glu-Cys-Gln-Lys-Leu-Leu-Gln-Ala-(SEQ ID NO;

     31),

(f) -Asp-Pro-Ile-Leu-Arg-Ser-Leu-Ala-Tyr-Ser-Asn-Ala-Asn-Lys-Glu-Cys-Gln-Lys-Leu- (SEQ ID NO;

     32),

(g) -Gly-Asp-Tyr-Ser-Pro-Ser-Cys-Cys-Thr-Leu-Thr-Ile-Gly-Val-Ser-Ser-Tyr-His-Ser-Lys-Pro-Cys-Asn-Pro-Ala-Gln-Pro-Val-Cys-Ser-(SEQ ID NO;

     33),

(h) -Thr-Lys-Lys-Pro-Asn-Arg-Asn-Gly-Gly-Gly-Tyr-Tyr-Ser-Ala-Ser-Tyr-Ser-Asp-Pro-Cys-Ser-Leu-Lys-Cys-Pro-Tyr-Leu- (SEQ ID NO;

     34),

(i) -Phe-Leu-Asn-Thr-Glu-Pro-Ser-Gln-Leu-Pro-Pro-Thr-Ala-Pro-Pro-Leu-Leu-Pro-His-Ser-Asn-Leu-Asp-His-Ile- (SEQ ID NO;

     3),

(j) -Thr-Pro-Leu-Leu-Tyr-Pro-Ser-Leu-Ala-Leu-Pro-Ala-Pro-His-Leu-Thr-Leu-Pro-Phe-Asn-Trp-Thr-His-Cys-Phe-Asp-Pro-Gln-Ile-Gln-(SEQ ID NO;

     35),

(k) -Thr-Pro-Cys-His-Asn-Ser-Leu-Ile-Leu-Pro-Pro-Phe-Ser-Leu-Ser-Pro-Val-Pro-Thr-Leu-Gly-Ser-Arg-Arg-Ala-Val-Pro-Val-Ala- (SEQ ID NO;

     36),

(l) -Val-Asp-Lys-Asp-Ile-Ser-Gln-Leu-Thr-Gln-Ala-Ile-Val-Lys-Asn-His-Lys-Asn-Leu-Leu-Lys-Ile-Ala-Gln-Tyr-Ala-Ala-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe- (SEQ ID NO;

     37),

(m) -Cys-Arg-Phe-Pro-Asn-Ile-Thr-Asn-Ser-His-Val-Pro-Ile-Leu-Gln-Glu-Arg-Pro-Pro-Leu-Glu-Asn-Arg-Val-Leu-Thr-Gly-Trp-Gly-Leu- (SEQ ID NO;

     38),

(n) -Leu-Ala-Gly-Pro-Cys-Ile-Leu-Arg-Gln-Leu-Arg-His-Leu-Pro-Ser-Arg-Val-Arg-Tyr-Pro-His-Tyr-Ser-Leu-Ile-Lys-Pro-Glu-Ser-Ser-Leu- (SEQ ID NO;

     39),

(o) -Tyr-Ala-Ala-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu- (SEQ ID NO;

     2), and

(p) -Leu-Leu-Pro-His-Ser-Asn-Leu-Asp-His-Ile-Leu-Glu-Pro-Ser-Ile-Pro-Trp-Lys-Ser-Lys- (SEQ ID NO;

     40),

2. The peptide according to claim 1 wherein A is a peptide fragment of the following amino acid sequence (SEQ ID NO:

1);

##STR29##

3. The peptide according to claim 1 wherein A is a peptide fragment of the following amino acid sequence (SEQ ID NO:

2);

##STR30##

4. The peptide according to claim 1 wherein A is a peptie fragment of the following amino acid sequence (SEQ ID NO:

3);

##STR31##